The ASCERTAIN V clinical trial demonstrated that an all-oral drug combination for older patients with acute myeloid leukemia ...
The resubmission follows a successful appeal by the company with the Office of New Drugs (OND). Outlook Therapeutics has resubmitted its Biologics License Application (BLA) to the US Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results